

Special Issue

A Personalized Medicine Approach to the Diagnosis and Management of Autism Spectrum Disorder: Beyond Genetic Syndromes

Message from the Guest Editors

Autism spectrum disorder (ASD) now affects more than 2% of children, and its prevalence continues to grow. Currently, there is no curative treatment and current therapies provide suboptimal habilitation in many individuals that are affected, leading to a new framing of ASD as a lifelong disorder for many rather than simply a disorder isolated to childhood. A majority of research on ASD concentrates on identifying the genetic syndrome, but there is a new understanding that the etiology of ASD is very complex and probably driven by genetic variations and vulnerabilities interacting with environmental exposures and triggers. Our two previous Special Issues have provided insight into applying personalized medicine to improve the diagnosis and detection of pathophysiological processes and predict treatment response in individuals with ASD. This year, we focus on the emerging understanding of the role of environmental factors, their contribution to genetic variants and vulnerabilities, and their interaction with the environment.

Guest Editors

Prof. Dr. Richard E. Frye


Dr. Richard Boles

Dr. Daniel Rossignol

Dr. Shannon Rose

Deadline for manuscript submissions

closed (30 April 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed




mdpi.com/si/153987

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).